Fundraising FoxNX Prenatal
Louisville, US · Founded 2013 · Delaware corporation · 6 known investors
Find your way into NX Prenatal
Sign up to see every warm intro you have to NX Prenatal
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NX Prenatal team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NX Prenatal is a molecular diagnostics company developing exosome-based liquid biopsy assays that detect adverse pregnancy conditions such as preterm birth, preeclampsia, and placenta accreta. Its non-invasive tests help physicians identify at-risk pregnancies to intervene and reduce complications for mother and child.
Founders & leadership
Investors · 6
How we know: Belle Impact Fund's portfolio page · Not right? Tell us
How we know: Keyhorse Capital's portfolio page · Not right? Tell us
How we know: Solas BioVentures's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$8.6M disclosed across 4 rounds · 2017–2023
▶$3.1MraisedAug 2023 · 20 investors · Other Health CareRule 506(b)
- ROBERT SAUNDERSDirector
- GAIL PAGEExecutive Officer, Director
- BRIAN BROHMANExecutive Officer
- DAVID ADAIRDirector
- ALAN MACKDirector
- Offering amount
- $15M
- Amount sold
- $3.1M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedAug 2021 · 47 investors · Other Health CareRule 506(b)
- Alan MackDirector
- Gail PageExecutive Officer, Director
- Brian BrohmanExecutive Officer, Director
- David AdairDirector
- Robert SaundersDirector
- Mary Lake PolanDirector
- Offering amount
- $6M
- Amount sold
- $5M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$72KraisedNov 2020 · 3 investors · Other Health CareRule 506(b)
- Mary Lake PolanDirector
- Alan MackDirector
- Robert SaundersDirector
- David AdairDirector
- Gail PageExecutive Officer, Director
- Brian BrohmanExecutive Officer
- Offering amount
- $72K
- Amount sold
- $72K
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$427.5KraisedNov 2017 · 28 investors · Other Health CareRule 506(b)
- GAIL PAGEExecutive Officer, Director
- BRIAN BROHMANExecutive Officer, Director
- ROBERT SAUNDERSDirector
- KEVIN BRAMERDirector
- ALAN MACKDirector
- Offering amount
- $1M
- Amount sold
- $427.5K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as NX Prenatal.
Frequently asked questions
- What does NX Prenatal do?
- NX Prenatal is a molecular diagnostics company developing exosome-based liquid biopsy assays that detect adverse pregnancy conditions such as preterm birth, preeclampsia, and placenta accreta. Its non-invasive tests help physicians identify at-risk pregnancies to intervene and reduce complications for mother and child.
- Who are NX Prenatal's investors?
- NX Prenatal's investors include Belle Impact Fund, Keyhorse Capital, Mindshift Capital, Solas BioVentures, Golden Seeds, Portfolia.
- How much funding has NX Prenatal raised?
- NX Prenatal has disclosed $8.6M raised across 4 rounds.
- Where is NX Prenatal headquartered?
- NX Prenatal is headquartered in Louisville, US.